Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Abbott Laboratories (Pakistan) (KAR:ABOT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Abbott Laboratories (Pakistan)'s EV-to-EBIT for today is
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil.
Abbott Laboratories (Pakistan)'s EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨14,119 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Abbott Laboratories (Pakistan)'s EV-to-EBITDA for today is:
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil.
Abbott Laboratories (Pakistan)'s EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨16,050 Mil.
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil.
Abbott Laboratories (Pakistan)'s Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨75,756 Mil.
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil.
Abbott Laboratories (Pakistan)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨9,362 Mil.
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil.
Abbott Laboratories (Pakistan)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨6,249 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) Enterprise Value Related Terms
Abbott Laboratories (Pakistan) Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) Enterprise Value Chart
KAR:ABOT vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories (Pakistan) Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s Enterprise Value distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories (Pakistan)'s Enterprise Value falls into.
Abbott Laboratories (Pakistan) Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Enterprise Value of ₨85,445 Mil as of Jul. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Abbott Laboratories (Pakistan) and its competitors.
Is Abbott Laboratories (Pakistan)'s Enterprise Value too high?
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Enterprise Value compare to ZTS and UTHR?
Abbott Laboratories (Pakistan)'s Enterprise Value of ₨85,445 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Abbott Laboratories (Pakistan) and its competitors. Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨85,445 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,003.35, compared to a current price of ₨995.32 — trading 0.8% below its estimated fair value. The current Enterprise Value is ₨85,445 Mil. Abbott Laboratories (Pakistan)'s overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Enterprise Value is ₨85,445 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨995.32 is trading 0.8% below its estimated GF Value™ of ₨1,003.35.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
Enterprise Value: ₨85,445 Mil
GF Value™: ₨1,003.35 vs. price of ₨995.32 (0.8% below fair value)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
77GF Score
Get the complete analysis for KAR:ABOT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
